Entering text into the input field will update the search result below

While Waiting For U.S. Correction, Try These China Names

Jan. 20, 2021 12:56 PM ET
WMA, LLC profile picture
WMA, LLC's Blog
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.


  • U.S. will be correcting soon.
  • But opportunities abound outside U.S.
  • Today we are putting on these position trades in Chinese companies.

January 20, 2021

We are expecting some form of market pull-back in the coming days or weeks. Over the recent few years, the period from end January to April has been problematic. Obviously last year we had Covid. In 2019, markets were fine because we got a big sell-off in December 2018. In 2018 we had a major drop in the S&P 500 both at the end of January and the end of March. 2017 was fine, but this was coming off the pre-election low of 2016. In January to March of 2016, we got a -12% correction. And so forth. Bottom line, we are not going to be looking aggressively for new positions, but we continue to run the models and look for “one-offs”.

Today we did find a stock that we’d buy right now: PetroChina.

Fundamentals are excellent:

And the chart is compelling:

We’ll load up BOTH the Natural Resources strategy and QES strategy with PTR. We need more Energy exposure in both strategies.

Another stock that we really like is Sinopharm.

Fundamentals: check

Chart: check

We’ll put Sinopharm in the QES. The ADR (OTCPK:SHTDY) is liquid enough for a position trade.

Another China phama, Shanghai Pharma, looks very similar: great fundamental score and price chart re-accelerating from lows.

The ADR is less liquid, but we’ll look at the bid/ask on the open and make a decision to add this one as well to the QES. The shares in Hong Kong are super-liquid, but in our QES Master Account at Interactive Advisors, we cannot buy the foreign shares.

A third stock we’ll buy pre-correction is WH Group.

WH’s chart is in the lower-mid portion of a stable multi-year range:

We’ll add this Staple to the QES via the WHGLY. The 4.5% dividend paid semi-annually is enticing.

Still on the China theme, we will add two transportation stocks. This is a “Covid is so overpriced” trade.

Guangshen Railway is C-H-E-A-P.

The chart is more hopeful than a typical wipe-out stock chart because we now see the rising bottoms on the oscillators.

Guangshen Railway’s ADR (OTCPK:GSHHY) will be our choice, even if we have to pay the bid/ask.

The other transportation stock is China Southern Airlines. Price is holding above a rising 200-day MA.

The fundamental numbers look good:

We have a 3rd China transportation stock that we recommend buying for accounts that take HKD. We just bought in our company trading account Shenzen Expressway :

The ADR was de-listed, but the 0548.HK trades well.

Again, for trading on Hong Kong, we’ll also be buying this utility:

A final China stock is Huaneng Power, which is a Value stock. The dividend paid is questionable because of a Payout ratio above 100% (hence the Strong Sell on Yield Rating).

The chart of Huaneng is hopeful, with price cracking above the 200-day MA. The shares trade on the U.S.

Otherwise, we are noting daily signals of Watch List in our Excel real-time sheet. In the event of a pull-back on no news (thus likely small), we’ll use some of these names in our portfolios.

We are running our models daily and "see" over 5000 stocks around the world.  And each day we find great entry points into our top (Watch List) stocks, filtered by fundamental scoring.  We offer our readers our invaluable research, which as seen above, will immensely improve your portfolio performance.  Sign-up and join us in finding the next winning stocks before the crowd does!

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.